CN108727497A - A kind of CD19 antibody and its application - Google Patents
A kind of CD19 antibody and its application Download PDFInfo
- Publication number
- CN108727497A CN108727497A CN201710250954.1A CN201710250954A CN108727497A CN 108727497 A CN108727497 A CN 108727497A CN 201710250954 A CN201710250954 A CN 201710250954A CN 108727497 A CN108727497 A CN 108727497A
- Authority
- CN
- China
- Prior art keywords
- antibody
- sed
- application
- cell
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
A kind of CD19 antibody of present invention offer and its application, are related to a kind of biology techniques field.Invention CD19 antibody has heavy chain variable region and light chain variable region, and CD19 antibody, which is chiefly used in preparing, is used for tumor vaccine cells, the immune application promised in drug of enhancing T cell.The present invention can be used for the immune immunogene of tumour cell, and enhancing T cell is immune to be promised, have that molecular weight is small, specific immunogenic is strong.
Description
Technical field
The present invention relates to a kind of biology techniques fields, more particularly to a kind of CD19 antibody and its application.
Background technology
CD19 has expression in normal and malignant B, is considered as in B cell growth course one and covers the stage
Longer surface marker the most reliable, in normal lymphoid tissue, CD19 is expressed in B cell and the folliculus tree of centrum germinativum
The dendron in T cell area grows cell between prominent shape cell, jacket cell, folliculus.
CD19 is typically considered the imbalance for the treatment of B cell or disease such as B cell malignant tumour, and autoimmunity disease and transplanting are arranged
The therapy target of reprimand is expressed in B cell system malignant tumour, therefore those skilled in the art are dedicated to developing and CD19 spies
The antibody that the opposite sex combines.Then, it is still difficult to for the antibody performance of CD19 at present satisfactory.
Invention content
Shortcoming present in regarding to the issue above, a kind of CD19 antibody of present invention offer and its application, can be used for swelling
The immune immunogene of oncocyte, enhancing T cell is immune to be promised, has that molecular weight is small, specific immunogenic is strong.
To solve the above-mentioned problems, the present invention provides a kind of CD19 antibody, wherein the antibody have heavy chain variable region and
Light chain variable region.
Preferably, the heavy chain variable region includes following three complementary determining region CDR：
SED ID NO：CDR1 shown in 5,
SED ID NO：CDR2 shown in 6, and
SED ID NO：CDR3 shown in 7.
Preferably, the light chain variable region includes following three complementary determining region CDR：
SED ID NO：CDR1 ' shown in 11,
SED ID NO：CDR2 ' shown in 12, and
SED ID NO：CDR3 ' shown in 13.
Preferably, the CD19 antibody has heavy chain as claimed in claim 2 and light chain as claimed in claim 3.
A kind of application of CD19 antibody, wherein the CD19 antibody, which is chiefly used in preparing, is used for tumor vaccine cells, enhances T
Cellular immunity promises the application in drug.
Preferably, the CD19 antibody is used to prepare the application of CAR-T cellular immunotherapies.
Compared with prior art, the present invention has the following advantages：
The CD19 immune antiboidies of the present invention are completely new sequence, the immunogene that can be used in tumor vaccine cells technology.It can
It to promote T cell, can effectively be specifically bound with the MHC on T cell surface, promote the combination of T cell and tumour cell, application
In cell therapies such as CAR-T.
Specific implementation mode
In order to make the purpose , technical scheme and advantage of the present invention be clearer, the present invention is made with reference to example
It is further described, but example is not as a limitation of the invention.
The embodiment of the present invention includes a kind of CD19 antibody and its application, can be used for the immune immunogene of tumour cell, increases
Strong T cell is immune to be promised, has that molecular weight is small, specific immunogenic is strong.
To solve the above-mentioned problems, the present invention provides a kind of CD19 antibody, wherein antibody has heavy chain variable region and light chain
Variable region.
Heavy chain variable region includes following three complementary determining region CDR：
SED ID NO：CDR1 shown in 5,
SED ID NO：CDR2 shown in 6, and
SED ID NO：CDR3 shown in 7.
Light chain variable region includes following three complementary determining region CDR：
SED ID NO：CDR1 ' shown in 11,
SED ID NO：CDR2 ' shown in 12, and
SED ID NO：CDR3 ' shown in 13.
CD19 antibody has heavy chain as claimed in claim 2 and light chain as claimed in claim 3.
A kind of application of CD19 antibody, wherein CD19 antibody, which is chiefly used in preparing, is used for tumor vaccine cells, enhances T cell
The immune application promised in drug.
CD19 antibody is used to prepare the application of CAR-T cellular immunotherapies.
The heavy chain variable region of antibody of the present invention includes following three complementary determining region CDR：
CDR1, amino acid sequence are GYSFTDYT (SEQ ID NO：5), coding nucleotide sequence is,
GGTTACTCATTCACTGACTACACC(SED ID NO：8)；
CDR2, amino acid sequence are INPYTGGT (SEQ ID NO：6), coding nucleotide sequence is,
ATTAATCCTTACACTGGTGGTACT(SED ID NO：9)；
CDR3, amino acid sequence are ARWDYRYDGGAMDY (SEQ ID NO：7), coding nucleotide sequence is,
GCAAGATGGGACTATAGGTACGACGGGGGTGCTATGGACTAC(SED ID NO：10).
The light chain variable region of antibody of the present invention includes following three complementary determining region CDR：
CDR1 ', amino acid sequence are KSVSTSGYSY (SEQ ID NO：11), coding nucleotide sequence is,
AAAAGTGTCAGTACATCTGGCTATAGTTAT(SED ID NO：14)；
CDR2 ', amino acid sequence are LVS (SEQ ID NO：12), coding nucleotide sequence is CTTGTATCC
(SED ID NO：15)；
CDR3 ', amino acid sequence are QHIRELTRSEGGPSWK (SEQ ID NO：13), coding nucleotide sequence
For CAGCACATTAGGGAGCTTACACGTTCGGAGGGGGGACCAAGATGGAAA (SED ID NO：16).
The foregoing description of the disclosed embodiments enables those skilled in the art to implement or use the present invention.
Various modifications to these embodiments will be apparent to those skilled in the art, as defined herein
General Principle can be realized in other embodiments without departing from the spirit or scope of the present invention.Therefore, of the invention
It is not intended to be limited to the embodiments shown herein, and is to fit to and the principles and novel features disclosed herein phase one
The widest range caused.
Claims (6)
1. a kind of CD19 antibody, which is characterized in that the antibody has heavy chain variable region and light chain variable region.
2. a kind of CD19 antibody as described in claim 1, which is characterized in that the heavy chain variable region includes following three complementations
Determine area CDR：
SED ID NO：CDR1 shown in 5,
SED ID NO：CDR2 shown in 6, and
SED ID NO：CDR3 shown in 7.
3. a kind of CD19 antibody as described in claim 1, which is characterized in that the light chain variable region includes following three complementations
Determine area CDR：
SED ID NO：CDR1 ' shown in 11,
SED ID NO：CDR2 ' shown in 12, and
SED ID NO：CDR3 ' shown in 13.
4. a kind of CD19 antibody as described in claim 1, which is characterized in that the CD19 antibody has such as claim 2 institute
The heavy chain and light chain as claimed in claim 3 stated.
5. a kind of application of CD19 antibody, which is characterized in that the CD19 antibody, which is chiefly used in preparing, is used for tumor vaccine cells, increases
The strong immune application promised in drug of T cell.
6. a kind of application of CD19 antibody as claimed in claim 4, which is characterized in that the CD19 antibody is used to prepare CAR-
The application of T cell immunization therapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710250954.1A CN108727497A (en) | 2017-04-17 | 2017-04-17 | A kind of CD19 antibody and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710250954.1A CN108727497A (en) | 2017-04-17 | 2017-04-17 | A kind of CD19 antibody and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108727497A true CN108727497A (en) | 2018-11-02 |
Family
ID=63925236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710250954.1A Pending CN108727497A (en) | 2017-04-17 | 2017-04-17 | A kind of CD19 antibody and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108727497A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021223719A1 (en) * | 2020-05-08 | 2021-11-11 | 亘喜生物科技（上海）有限公司 | Antibody directed against cd19 antibody, and preparation therefor and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104583230A (en) * | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
| CN104788573A (en) * | 2015-05-08 | 2015-07-22 | 中国医学科学院血液病医院（血液学研究所） | Chimeric antigen receptor hCD19scFv-CD8a-CD-28-CD3zata and application thereof |
| CN105837689A (en) * | 2015-01-13 | 2016-08-10 | 博生吉医药科技(苏州)有限公司 | Anti-CD19 monoclonal antibody and preparation method thereof |
| CN106220739A (en) * | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | The purposes of the T cell treatment cancer that Chimeric antigen receptor is modified |
-
2017
- 2017-04-17 CN CN201710250954.1A patent/CN108727497A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106220739A (en) * | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | The purposes of the T cell treatment cancer that Chimeric antigen receptor is modified |
| CN104583230A (en) * | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
| CN105837689A (en) * | 2015-01-13 | 2016-08-10 | 博生吉医药科技(苏州)有限公司 | Anti-CD19 monoclonal antibody and preparation method thereof |
| CN104788573A (en) * | 2015-05-08 | 2015-07-22 | 中国医学科学院血液病医院（血液学研究所） | Chimeric antigen receptor hCD19scFv-CD8a-CD-28-CD3zata and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021223719A1 (en) * | 2020-05-08 | 2021-11-11 | 亘喜生物科技（上海）有限公司 | Antibody directed against cd19 antibody, and preparation therefor and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3459597T3 (en) | Single domain antibody for ctla4 and derived protein thereof | |
| Liu et al. | Gene-based vaccines and immunotherapeutics | |
| CN107050440B (en) | Vaccine compositions and methods of use thereof | |
| JP2019511222A5 (en) | ||
| JP2014534202A5 (en) | ||
| CN107072184A (en) | Chimeric antigen receptor | |
| JP2017029157A5 (en) | ||
| JP2018509936A5 (en) | ||
| CN108025048A (en) | Shared neoantigen | |
| Wang et al. | Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy | |
| JP2009523422A5 (en) | ||
| JP2018535668A5 (en) | ||
| EP4269438A3 (en) | Oncolytic virus and method | |
| Di Bonito et al. | Anti-cancer vaccine for HPV-associated neoplasms: focus on a therapeutic HPV vaccine based on a novel tumor antigen delivery method using endogenously engineered exosomes | |
| Gupta et al. | Recent advances in cancer vaccines: challenges, achievements, and futuristic prospects | |
| CN103768595A (en) | Zoledronic acid adjuvant and vaccine containing same | |
| JP2014139185A5 (en) | ||
| Mohsen et al. | Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma | |
| Park et al. | Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine | |
| CN108727497A (en) | A kind of CD19 antibody and its application | |
| CN107058231A (en) | Carry recombined adhenovirus of antigen-4 fusion protein gene and its preparation method and application | |
| RU2020115161A (en) | DNA MONOCLONAL ANTIBODIES AGAINST CTLA-4 FOR TREATMENT AND PREVENTION OF CANCER | |
| CN110964104A (en) | Protein capable of binding HPV18 virus and application thereof | |
| RU2018126487A (en) | CANCER VACCINES | |
| MX2012004448A (en) | Infectious clones of torque teno virus. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181102 |
|
| RJ01 | Rejection of invention patent application after publication |